Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores ...

Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...

Monday, Immutep said a combination of eftilagimod and Merck & Co.’s Keytruda helped patients live a median of 17.6 months when used as first-line therapy in patients with recurrent or metastatic ...

Keytruda (pembrolizumab) is a prescription drug used to treat certain types of cancer in adults and some children. Keytruda isn’t known to interact with alcohol, other medications, or ...

Phase 1b/2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda ® when administered via Interventional Radiology (IR) in patients with deep- seated ...

The combination of anti-PD-1 therapy Keytruda with tyrosine kinase inhibitor Inlyta (axitinib) reduced risk of death in RCC by around 47%, compared with Pfizer’s established cancer drug Sutent ...

Keytruda (pembrolizumab) is an FDA-approved immunotherapy treatment for cancer that is covered by Medicare Part B as an outpatient infusion. Without insurance, a single 200-milligram dose of ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

This part of the Phase II study evaluates eftilagimod alfa (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first line ...